Formulating Poorly Water Soluble Drugs

Robert O. (Bill) Williams III, Ph.D. is the Johnson & Johnson Centennial Professor of Pharmaceutics at the College of Pharmacy, University of Texas at Austin.  He earned a B.S. in Biology from Texas A&M University, a B.S. in Pharmacy from the University of Texas at Austin and Doctor of Philosophy in Pharmaceutics in 1986 from the University of Texas at Austin.  Dr. Williams worked 9 years in the pharmaceutical industry in the United States and France before returning to the University of Texas at Austin.  Dr Williams was elected a Fellow of the American Association of Pharmaceutical Scientists in 2006 and a Fellow of the American Institute of Medical and Biological Engineering in 2008.  Dr. Williams is a member of numerous professional organizations, including American Association of Colleges of Pharmacy, and American Association of Pharmaceutical Scientists. Dr. Williams’ research interests include development of novel drug delivery systems for oral, pulmonary, nasal, injectable, buccal and topical applications, development of novel particle engineering technologies for low molecular weight drugs, peptides and proteins, and analytical technologies to characterize actives, excipients and polymers.  He has published over 300 articles, abstracts and book chapters in the fields of pharmaceutical technology and drug delivery.  In addition, Dr. Williams has co-edited one book.  He is an inventor on numerous patents and patent applications.  Dr. Williams is the Editor-in-Chief of the research journal Drug Development and Industrial Pharmacy, and serves as a reviewer for International Journal of Pharmaceutics, Pharmaceutical Research, European Journal of Pharmaceutics and Biopharmaceutics, S.T.P. Pharma Sciences, AAPS PharmSciTech, Journal of Pharmaceutical Sciences, Pharmaceutical Development and Technology, Journal of Membrane Science, and Journal of ControlledRelease.   Alan B. Watts, Ph.D. is the Assistant Director of the Drug Dynamics Institute and an Adjunct Assistant Professor at the College of Pharmacy, University of Texas at Austin.  He earned a B.S. in Biomedical Engineering from Louisiana Tech University and Doctor of Philosophy in Pharmaceutics from the University of Texas at Austin where he was an AAPS/AFPE Pre-Doctoral Fellow.  His research efforts have focused on novel approaches toward pulmonary drug delivery, translational science, and formulation of insoluble drugs.  Previously, Alan worked as a Research Scientist in the pharmaceutical industry specializing in drugs for dry powder delivery to the lungs.   Dave Miller, Ph.D. is a Senior Principal Scientist in the Pharmaceutical and Analytical Research and Development Department at Hoffmann-La Roche, Inc. in Nutley, NJ. He earned his B.S. in Chemical Engineering in 2002 and his Ph.D. in Pharmaceutics in 2007 from the University of Texas at Austin. Throughout his academic and industrial career, Dr. Miller’s research focus has been in the area of solubility enhancement; specifically, advanced solid dispersion systems, hot-melt extrusion technology, spray drying technology, precipitation technology, and the development of in-vitro/in-vivo relationships. He has published numerous research articles, two book chapters, and is a co-inventor on several patent applications pertaining to this field.

Route-Specific Challenges in Delivery of Poorly Water Soluble Drugs.- Optimizing the Formulation of Poorly Water Soluble Drugs.- Solid-State Techniques for Improving Solubility.- Mechanical Particle Size Reduction Techniques.- Solubilized Formulations.- Injectable Formulations of Poorly Water Soluble Drugs.- Design and Development of Self-Emulsifying Lipid Formulations for Improving Oral Bioavailability of Poorly Water-Soluble and Lipophilic Drugs.- Structured Development Approach for Amorphous Systems.- Melt Extrusion.- Spray Drying Technology.- Pharmaceutical Cryogenic Technologies.- Precipitation Technologies for Nanoparticle Production.- Emerging Technologies to Increase the Bioavailability of Poorly Water Soluble Drugs.- Regulatory Considerations for Development and Commercialization of Poorly Water Soluble Drugs.